Advertisement

Psychopharmacologia

, Volume 1, Issue 1, pp 20–28 | Cite as

Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25)

  • Harris Isbell
  • E. J. Miner
  • C. R. Logan
Article

Summary

  1. 1.

    The psychotomimetic potency of 13 congeners of LSD-25 has been approximately determined in man.

     
  2. 2.

    With the exception of acetylation of the indole nitrogen, all the changes made in the LSD molecule reduced psychotomimetic potency. Bromination at carbon 2 caused the greatest inactivation.

     
  3. 3.

    High potency as a serotonin antagonist in isolated smooth muscle preparations was not correlated with high potency as a psychotomimetic.

     
  4. 4.

    The data do not support but do not disprove the “serotonin deficiency” hypothesis of the LSD psychosis.

     

Keywords

Nitrogen Smooth Muscle Serotonin Indole High Potency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramson, H. A., M. E. Jarvik, M. R. Kaufman, C. Kornetsky, A. Levine and M. Wagner: Lysergic acid diethylamide (LSD-25). I. Physiological and perceptual responses. J. Psychol. (Provincetown), 39, 3 (1955).Google Scholar
  2. — and M. D. Baron: Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-Metlryl-d-lysergic acid diethylamide). A.M.A. Arch. Neurol. Psychiat. 79, 201–207 (1958).Google Scholar
  3. Cerletti, A., and W. Doepfner: Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J. Pharmacol. exp. Ther. 122, 124–136 (1958).PubMedGoogle Scholar
  4. Cerletti, A., and E. Rothlin: Role of 5-Hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives. Nature (Lond.) 176, 785–786 (1955).Google Scholar
  5. Gaddum, J. H.: Ciba Foundation Symposium on Hypertension. London: Churchill 1953.Google Scholar
  6. Geronimus, L. H., H. A. Abramson and L. J. Ingraham: Lysergic acid diethylamide (LSD-25). XXIII. Comparative effects of LSD-25 and related ergot drugs on brain tissue respiration and on human behavior. J. Psychol. (Provincetown) 42, 157–168 (1956).PubMedGoogle Scholar
  7. Gogerty, J. H., and J. M. Dille: Pharmacology of d-lysergic acid morpholide (LSM). J. Pharmacol. exp. Ther. 120, 340–348 (1957).PubMedGoogle Scholar
  8. Isbell, H., R. E. Belleville, H. F. Fraser, A. Wikler and C. R. Logan: Studies on lysergic acid diethylamide. I. Effects in former morphine addicts and development of tolerance during chronic intoxication. A.M.A. Arch. Neurol. Psychiat. 76, 468–478 (1956).Google Scholar
  9. C. R. Logan and E. J. Miner: Studies on the diethylamide of lysergic acid (LSD-25). III. Attemptsto attenuate the LSD-reaction in man by pretreat ment with neuro-humoral blocking agents. A.M.A. Arch. Neurol. Psychiat (in press)Google Scholar
  10. Jarvik, M. E., H. A. Abramson and M. W. Hirsch: Comparative subjective effects of seven drugs including lysergic acid diethylamide (LSD-25). J. abnorm. soc. Psychol. 51, 657–622 (1955).Google Scholar
  11. Murphree, H. B., E. W. J. DeMaar, H. L. Williams and L. L. Bryan: Effects of lysergic acid derivatives on man; antagonism between d-lysergic acid diethylamide and its 2-Bromcongener (Abstract). J. Pharmacol. exp. Ther. 122, 55a-56a (1958).Google Scholar
  12. Page, I. H.: Serotonin (5-Hydroxytryptamine); the last four years. Physiol. Rev. 38, 277–335 (1958).PubMedGoogle Scholar
  13. Rinaldi, F., L. H. Rudy and H. E. Himwich: Clinical evaluation of azacyclonol, chlorpromazine and reserpine on a group of chronic psychotic patients. Amer. J. Psychiat. 112, 678–683 (1956).PubMedGoogle Scholar
  14. Rothlin, E.: Lysergic acid diethylamide and related substances. Ann. N. Y. Acad. Sci. 66, 668–676 (1957).PubMedGoogle Scholar
  15. Schneckloth, R., I. H. Page, F. Del Greoo and A. C. Corcoran: Effects of serotonin antagonists in normal subjects and patients with carcinoid tumors. Circulation 16, 523–532 (1957).PubMedGoogle Scholar
  16. Shore, P. A., S. L. Silver and B. B. Brodie: Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia (Basel) 11, 272–273 (1955).Google Scholar
  17. Snow, P. J. D., J. E. Lennard-Jones, G. Curzon, and R. S. Stacy: Humoral effects of metastasizing carcinoid tumors. Lancet 1955II, 1004–1009.Google Scholar
  18. Solms, H.: Lysergsäure-äthylamid (LAE), ein neues stark sedativ wirkendes Psychoticum aus dem Mutterkorn. Schweiz. med. Wschr. 83, 356–360 (1953).PubMedGoogle Scholar
  19. Solms, H.: Relationship between chemical structure and psychoses with the use of psychotoxic substances. J. clin. Psychopath. 17, 429–433 (1956).Google Scholar
  20. Winter, C. A., and L. Flataker: Studies on heptazone (6-Morpholino-4,4-diphenyl-3-heptanone hydrochloride) in comparison with other analgesic agents. J. Pharmacol. exp. Ther. 98, 305–317 (1950).Google Scholar
  21. Wooley, D. W., and E. Shaw: A biochemical and pharmacological suggestion about certain mental disorders. Proc. nat. Acad. Sci. (Wash.) 40, 228–231 (1954a). - Some neurophysiological effects of serotonin. Brit. med. J. 1954b, 122–126.Google Scholar

Copyright information

© Springer-Verlag 1959

Authors and Affiliations

  • Harris Isbell
    • 1
  • E. J. Miner
    • 1
  • C. R. Logan
    • 1
  1. 1.National Institute of Mental Health, Addiction Research CenterU. S. Public Health ServiceLexington

Personalised recommendations